Department of Gynecology Oncology, vali-e-asr hospital, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, 1419733141, Iran.
World J Surg Oncol. 2010 Feb 19;8:11. doi: 10.1186/1477-7819-8-11.
Prediction of optimal cytoreduction in patients with advanced epithelial ovarian caner preoperatively.
Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan. to June 2008 at gynecologic oncology ward of TUMS (Tehran University of Medical Sciences) were eligible for this study. The possibility of predicting primary optimal cytoreduction considering multiple variables was evaluated. Variables were peritoneal carcinomatosis, serum CA125, ascites, pleural effusion, physical status and imaging findings.Univariate comparisons of patients underwent suboptimal cytoreduction carried out using Fisher's exact test for each of the potential predictors. The wilcoxon rank sum test was used to compare variables between patients with optimal versus suboptimal cytoreduction.
41 patients met study inclusion criteria. Statistically significant association was noted between peritoneal carcinomatosis and suboptimal cytoreduction. There were no statistically significant differences between physical status, pleural effusion, imaging findings, serum CA125 and ascites of individuals with optimal cytoreduction compared to those with suboptimal cytoreduction.
Because of small populations in our study the results are not reproducible in alternate populations. Only the patient who is most unlikely to undergo optimal cytoreduction should be offered neoadjuvant chemotherapy, unless her medical condition renders her unsuitable for primary surgery.
预测术前晚期上皮性卵巢癌患者的最佳肿瘤细胞减灭术。
本研究纳入了 2008 年 1 月至 6 月在 TUMS(德黑兰医科大学)妇科肿瘤科首次接受手术的晚期上皮性卵巢癌患者。评估了考虑多种变量预测初次最佳肿瘤细胞减灭术的可能性。变量包括腹膜癌病、血清 CA125、腹水、胸腔积液、身体状况和影像学表现。对于每个潜在的预测因子,使用 Fisher 确切检验对行次优肿瘤细胞减灭术的患者进行单变量比较。Wilcoxon 秩和检验用于比较最佳肿瘤细胞减灭术和次优肿瘤细胞减灭术患者之间的变量。
41 例患者符合研究纳入标准。腹膜癌病与次优肿瘤细胞减灭术之间存在统计学显著关联。与行最佳肿瘤细胞减灭术的患者相比,行次优肿瘤细胞减灭术的患者在身体状况、胸腔积液、影像学表现、血清 CA125 和腹水方面无统计学差异。
由于本研究的患者人群较小,因此研究结果在其他人群中不可复制。只有最不可能行最佳肿瘤细胞减灭术的患者才应接受新辅助化疗,除非她的身体状况不适合行初次手术。